BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022

  Abivax will be hosting a Satellite Symposium on February 17, 2022, at 12:00-1:00 pm CET (6:00-7:00am ET) on ABX464’s potential to address unmet medical needs for the treatment of ulcerative colitis (UC).

  February 8, 2022

   · 

  4 min read
• Business

  Bactiguard and Zimmer Biomet expand global license partnership

  Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments.

  February 8, 2022

   · 

  2 min read
• Rehabilitation Robotics Market Size to Reach USD 11.38 Billion in 2028 | Industry Trend – Growing Adoption of Assistive Robotics in Treatment of Orthopedic Disorders

  According to Emergen Research, the global rehabilitation robotics market size was USD 2.77 billion in 2020 and is expected to reach USD 11.38 billion in 2028 and register a revenue CAGR of 20.5% during the forecast period, 2021-2028.

  February 8, 2022

   · 

  7 min read
• Business

  BioLife Sciences Inc. (OTC Markets: BLFE) Announced Today That the Company is Launching a New Life Sciences Division

  BioLife Sciences is pleased to announce the launching of a new life sciences division, aimed at honing in on disruptive technology and solutions with a focus on antimicrobial supported pomology, olericulture, floriculture and general plant sciences.

  February 8, 2022

   · 

  4 min read
• Business

  STERIS Announces Financial Results for Fiscal 2022 Third Quarter

  STERIS plc announced financial results for its fiscal 2022 third quarter ended December 31, 2021.

  February 8, 2022

   · 

  14 min read
• Drug Development

  Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851

  Cyteir Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monotherapy that is part of the Phase 1/2 trial. CYT-0851 is being evaluated for the treatment of hematologic malignancies and solid tumors.

  February 8, 2022

   · 

  4 min read
• BioMidwest

  Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference

  Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.

  February 8, 2022

   · 

  1 min read
• Business

  Medable Launches Partner Network to Accelerate Innovation and Simplify Deployment of Decentralized Clinical Trials

  Medable Inc. today launched the Medable Partner Network – uniting a diverse ecosystem of technology, service, data, site, and direct-to-patient partners that work together to accelerate deployment of decentralized clinical trials.

  February 8, 2022

   · 

  5 min read
• BioCapital

  NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

  NextCure, Inc. announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday February 16th at 10:40 am ET.

  February 8, 2022

   · 

  2 min read
• Pharm Country

  Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission No additional clinical work required; NDA resubmission anticipated in Q3 2022

  Eyenovia, Inc. today announced that the company successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) related to the refiling of the NDA for MydCombi.

  February 8, 2022

   · 

  5 min read